StockData
BridgeBio Oncology Therapeutics, Inc. logo

BridgeBio Oncology Therapeutics, Inc. (BBOT) bonds

BBOTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$2.14−0.21 (-8.94%)

Close on Nov 13, 2026Market cap $171.57MP/E –Yield –

Debt

Borrowings on the balance sheet, Sep 30, 2026

BridgeBio Oncology Therapeutics reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Notes and loans outstanding

Individual notes, bonds and loans

BridgeBio Oncology Therapeutics's filings do not break debt down by note

The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.

See a number that looks wrong?